SNRIs: mechanism of action and clinical features
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Specific serotonin and norepinephrine reuptake inhibitors are a relatively recent class of antidepressants which have specificities making them a therapeutic choice. They are characterized by a mixed action on both major neuroamines of depression: norepinephrine and serotonin. The double polarity of the reuptake inhibition of serotonin and norepinephrine ensures a profile of effectiveness comparable to tricyclic antidepressants and higher than selective serotonin reuptake inhibitors, especially in severe depression. The absence of affinity for muscarinic, histaminic and alpha1-adrenergic receptors and the absence of action on monoamine oxidase limits their adverse effects and allows them to be better tolerated than tricyclic antidepressants and similar to selective serotonin reuptake inhibitors. Currently, two drugs of this class are available, milnacipran and venlafaxine, but several more are in development. They are active on depressive symptoms, as well as on certain comorbid symptoms (anxiety, sleep disorders) frequently associated with depression. Serotonin and norepinephrine reuptake inhibitors allow an improved rate of response and a significant rate of remission, decreasing the risk of relapse and recurrence in the medium and long term. Due to their good tolerance, they can also be prescribed for long-term treatment and in high doses in refractory depression or with strong potential of relapse. For all these reasons, one can reasonably conclude that serotonin and norepinephrine reuptake inhibitors represent the therapeutic of choice in depression and that their prescription is likely to strongly increase in the years to come.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Entsuah, A. R., Huang, H., & Thase, M. E. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n1106 · Cited by 245
Rudolph, R. L., & Feiger, A. D. (1999) · Journal of Affective Disorders · doi:10.1016/s0165-0327(99)00067-1 · Cited by 158
Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study
Rouillon, F., Warner, B., Pezous, N., & Bisserbe, J. C. (2000) · International Clinical Psychopharmacology · doi:10.1097/00004850-200015030-00002 · Cited by 47
Pharmacodynamics of milnacipran in young and elderly volunteers
Hindmarch, I., Rigney, U., Stanley, N., & Briley, M. (2000) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2000.00124.x · Cited by 41
Cited by
Prado, C. E., Watt, S., & Crowe, S. F. (2018) · Neuropsychology Review · doi:10.1007/s11065-018-9369-5 · Cited by 188
Pharmacological treatment of chronic pain—The need for CHANGE
Varrassi, G., Müller-Schwefe, G., Pergolizzi, J., Orónska, A., Morlion, B., Mavrocordatos, P., Margarit, C., Mangas, C., Jaksch, W., Huygen, F., et al. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003689175 · Cited by 167
Anxiolytic-like effect of milnacipran in the four-plate test in mice: Mechanism of action
BOURIN, M., MASSE, F., DAILLY, E., & HASCOET, M. (2005) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2005.04.015 · Cited by 33
Self-citationGrammatopoulos, D. K. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.02.013 · Cited by 26
Metadata
- Authors
- Lambert, O., & Bourin, M.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2002-11
- Volume
- 2
- Issue
- 6
- Pages
- 849-858
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W2020713081
- Cited by
- 57
- References
- 4
- FWCI
- 0.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.